PDS Biotechnology Past Earnings Performance
Past criteria checks 0/6
PDS Biotechnology's earnings have been declining at an average annual rate of -42.9%, while the Biotechs industry saw earnings growing at 15.5% annually.
Key information
-42.9%
Earnings growth rate
-15.0%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | n/a |
Return on equity | -118.0% |
Net Margin | n/a |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
PDS Biotechnology: Promising Phase 2 With Cash Issues That Might Be Worth The Risk
Jan 13PDS Biotech jumps 13% as FDA clears further development of lead asset
Oct 03PDS Biotechnology files for $150 mixed shelf offering
Aug 24PDS Biotech spikes as panel backs continuation of cancer trial for lead asset
Aug 04PDS Biotechnology (NASDAQ:PDSB) Is In A Strong Position To Grow Its Business
Jul 08PDS Biotechnology: Speculative Biotech Worth Buying After Latest Data
May 27PDS Biotechnology: Versamune Platform Targeting HPV-Associated Cancers
Feb 22PDS Biotech: Looking Attractive Despite 52-Week High Price
Sep 19PDS Biotech under pressure after pricing equity offering at $8.50
Jun 15PDS Biotech announces preliminary efficacy readout from phase 2 combo trial of PDS0101
Feb 03PDS Biotechnology gives new CFO ~202K stock grant
Jan 06PDS Biotech launches mid-stage PDS0101 combo trial in head & neck cancer
Nov 10Revenue & Expenses Breakdown
How PDS Biotechnology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 0 | -44 | 15 | 29 |
31 Dec 23 | 0 | -43 | 15 | 28 |
30 Sep 23 | 0 | -51 | 15 | 36 |
30 Jun 23 | 0 | -48 | 14 | 34 |
31 Mar 23 | 0 | -42 | 13 | 30 |
31 Dec 22 | 0 | -41 | 12 | 29 |
30 Sep 22 | 0 | -28 | 13 | 17 |
30 Jun 22 | 0 | -28 | 13 | 16 |
31 Mar 22 | 0 | -22 | 12 | 15 |
31 Dec 21 | 0 | -17 | 10 | 11 |
30 Sep 21 | 0 | -15 | 9 | 10 |
30 Jun 21 | 0 | -12 | 7 | 9 |
31 Mar 21 | 0 | -14 | 7 | 7 |
31 Dec 20 | 0 | -15 | 7 | 8 |
30 Sep 20 | 0 | -15 | 7 | 7 |
30 Jun 20 | 0 | -17 | 8 | 7 |
31 Mar 20 | 0 | -18 | 9 | 7 |
31 Dec 19 | 0 | -7 | 11 | 6 |
30 Sep 19 | 0 | -5 | 11 | 5 |
30 Jun 19 | 0 | 0 | 8 | 3 |
31 Mar 19 | 0 | 4 | 6 | 2 |
31 Dec 18 | 0 | -4 | 3 | 1 |
30 Sep 18 | 0 | -2 | 2 | 1 |
31 Dec 17 | 0 | -3 | 1 | 2 |
Quality Earnings: PDSB is currently unprofitable.
Growing Profit Margin: PDSB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PDSB is unprofitable, and losses have increased over the past 5 years at a rate of 42.9% per year.
Accelerating Growth: Unable to compare PDSB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PDSB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: PDSB has a negative Return on Equity (-118.03%), as it is currently unprofitable.